Allergan Sees Hope In Poor Botox Depression Data
Executive Summary
Allergan has decided to pursue Botox in Phase III as a treatment for depression, despite a Phase II trial not meeting its primary endpoint and failing to show a dose response. One analyst has suggested the company is merely attempting to shore up off-label sales.